Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Upfront continuous BTK inhibitor (BTKi) versus time-limited venetoclax-BTKi combinations in CLL across IGHV subgroups: Results of an indirect analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

SMStefano MolicaDADavid Allsup

Discussion

Loading...

Member takes

Overview

Indirect analysis reveals similar four-year progression-free survival in CLL with venetoclax-BTKi or BTK inhibitors, suggesting flexible treatment strategies based on patient preferences.

Key Points

  • Four-year progression-free survival was comparable between treatment strategies in chronic lymphocytic leukemia.
  • A systematic review identified relevant phase III trials comparing BTK inhibitors and venetoclax-BTKi combinations.
  • Sensitivity analysis indicated no significant difference in four-year progression-free survival across IGHV subgroups.
  • The findings support personalized treatment selection in treatment-naïve, TP53 wild-type CLL patients.

Cite This Study

Molica et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d870https://doi.org/10.1182/blood-2025-3887
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world comparison of BTKi monotherapy and fixed-duration BTKi–Venetoclax for first line treatment of chronic lymphocytic leukemia patients without TP53 mutations or IGHV rearrangement2025
  2. 2Outcomes with a fixed duration combination of bruton tyrosine kinase inhibitors and venetoclax in chronic lymphocytic leukemia: A systematic review and meta-analysis2025
  3. 3Long-term outcomes in high-risk patients with chronic lymphocytic leukemia treated with targeted therapies in the real-world2025
  4. 4Fixed-duration versus continuous targeted treatment for previously untreated chronic lymphocytic leukemia: Results from the randomized CLL17 trial2025 · 4 citations
  5. 5Real‑world effectiveness and patient-centered outcomes of fixed‑duration vs continuous first‑line therapy in chronic lymphocytic leukemia (CLL)2025